CSIMarket
 


Denali Therapeutics Inc   (DNLI)
Other Ticker:  
 

Denali Therapeutics Inc 's Working Capital Ratio

DNLI's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the forth quarter 2023, Working Capital Ratio fell to 13.65 above Denali Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 4 other companies have achieved higher Working Capital Ratio than Denali Therapeutics Inc in forth quarter 2023. While Working Capital Ratio total ranking has improved so far during the IV Quarter 2023 to 150, from total ranking in the third quarter 2023 at 240.

Explain Working Capital Ratio
How much in Current Assets DNLI´s has?
What is the value of DNLI´s Current Liabilities?


DNLI Working Capital Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change -78.57 % -80.26 % -80.08 % 14.61 % -3.79 %
Y / Y Current Assets Change -22.46 % 0.38 % 9.82 % 34.07 % 52.95 %
Working Capital Ratio MRQ 13.65 16.06 17.65 3.39 3.77
DNLI's Total Ranking # 150 # 240 # 240 # 1128 # 1055
Seq. Current Liabilities Change 9.56 % 2.63 % -82.27 % 7.46 % 0.9 %
Seq. Current Assets Change -6.89 % -6.63 % -7.63 % -3.44 % 20.53 %



Working Capital Ratio forth quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 5
Healthcare Sector # 33
Overall Market # 150


Working Capital Ratio Statistics
High Average Low
26.22 12.23 2.37
(Mar 31 2021)   (Dec 31 2021)




Financial Statements
Denali Therapeutics Inc 's Current Liabilities $ 78 Millions Visit DNLI's Balance sheet
Denali Therapeutics Inc 's Current Assets $ 1,064 Millions Visit DNLI's Balance sheet
Source of DNLI's Sales Visit DNLI's Sales by Geography


Cumulative Denali Therapeutics Inc 's Working Capital Ratio

DNLI's Working Capital Ratio for the trailling 12 Months

DNLI Working Capital Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth -78.57 % -80.26 % -80.08 % 14.61 % -3.79 %
Y / Y Current Assets TTM Growth -22.46 % 0.38 % 9.82 % 34.07 % 52.95 %
Working Capital Ratio TTM 7.8 5.66 4.27 3.38 3.26
Total Ranking TTM # 183 # 587 # 888 # 1232 # 1461
Seq. Current Liabilities TTM Growth 9.56 % 2.63 % -82.27 % 7.46 % 0.9 %
Seq. Current Assets TTM Growth -6.89 % -6.63 % -7.63 % -3.44 % 20.53 %


On the trailing twelve months basis Current Liabilities decreased faster than Denali Therapeutics Inc 's average Current Assets, this led to increase in in Denali Therapeutics Inc 's Working Capital Ratio to 7.8, Working Capital Ratio remained below DNLI average.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 76 other companies have achieved higher Working Capital Ratio than Denali Therapeutics Inc . While Working Capital Ratio overall ranking has improved so far to 34, from total ranking during the twelve months ending third quarter 2023 at 1911.

Explain Working Capital Ratio
How much in Current Assets DNLI´s has?
What is the value of DNLI´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 77
Healthcare Sector # 499
Within the Market # 150


trailing twelve months Working Capital Ratio Statistics
High Average Low
22.95 9.64 2.9
(Sep 30 2021)   (Sep 30 2022)




Companies with similar Working Capital Ratio in the quarter ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Working Capital RatioDec 31 2023 MRQ Current AssetsDec 31 2023 MRQ Current Liabilities
Creative Medical Technology Holdings Inc   28.75 $ 10.271  Millions$ 0.357  Millions
Enzon Pharmaceuticals inc   27.62 $ 47.343  Millions$ 1.714  Millions
Estrella Immunopharma Inc   23.70 $ 9.447  Millions$ 0.399  Millions
Immunovant Inc   22.35 $ 710.776  Millions$ 31.796  Millions
Elevation Oncology inc   21.22 $ 87.964  Millions$ 4.145  Millions
Compass Therapeutics Inc   19.73 $ 153.881  Millions$ 7.801  Millions
Acumen Pharmaceuticals Inc   19.01 $ 246.615  Millions$ 12.971  Millions
Krystal Biotech Inc   17.76 $ 587.909  Millions$ 33.094  Millions
Voyager Therapeutics Inc   14.78 $ 319.684  Millions$ 21.627  Millions
Denali Therapeutics Inc   13.65 $ 1,064.137  Millions$ 77.982  Millions
Molecular Partners Ag  13.35 $ 192.459  Millions$ 14.416  Millions
Anavex Life Sciences Corp   12.79 $ 148.070  Millions$ 11.578  Millions
Replimune Group Inc   12.40 $ 479.164  Millions$ 38.650  Millions
Allogene Therapeutics inc   12.38 $ 459.115  Millions$ 37.079  Millions
Caribou Biosciences Inc   11.97 $ 338.841  Millions$ 28.302  Millions
Entera Bio Ltd   11.76 $ 11.257  Millions$ 0.957  Millions
Scholar Rock Holding Corp  11.38 $ 288.194  Millions$ 25.333  Millions
Century Therapeutics inc   9.92 $ 176.994  Millions$ 17.846  Millions
Argenx se  9.75 $ 4,123.737  Millions$ 422.993  Millions
Biontech Se  9.43 $ 21,870.576  Millions$ 2,318.960  Millions
Vir Biotechnology Inc   9.05 $ 1,588.226  Millions$ 175.407  Millions
Pharmacyte Biotech Inc   8.16 $ 61.508  Millions$ 7.539  Millions
Passage Bio inc   7.22 $ 117.959  Millions$ 16.341  Millions
Pluri Inc   7.12 $ 32.252  Millions$ 4.530  Millions
Fresh Tracks Therapeutics Inc   6.98 $ 11.552  Millions$ 1.656  Millions
Tarsus Pharmaceuticals Inc   6.93 $ 256.131  Millions$ 36.936  Millions
Black Diamond Therapeutics Inc   6.82 $ 134.034  Millions$ 19.646  Millions
Halozyme Therapeutics Inc   6.64 $ 746.424  Millions$ 112.494  Millions
Springworks Therapeutics Inc   6.41 $ 500.912  Millions$ 78.170  Millions
C4 Therapeutics Inc   6.34 $ 271.189  Millions$ 42.766  Millions

Date modified: 2024-02-28T20:36:20+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com